Biogen Says New Data From Investigational Antisense Oligonucleotide Targeting Tau Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Biogen Inc. (NASDAQ:BIIB) reported promising Phase 1b clinical data for its investigational antisense oligonucleotide (ASO) therapy, BIIB080, targeting tau in mild Alzheimer's disease. The data showed favorable trends on multiple exploratory endpoints of cognition and daily living activities. The study is the first to show a reduction of aggregated tau pathology and favorable trends on clinical outcomes with a tau targeting drug. Recruitment is underway for the Phase 2 CELIA study to further investigate clinical efficacy and safety.
October 25, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's investigational therapy, BIIB080, shows promising results in Phase 1b study for Alzheimer's disease. The company is recruiting for Phase 2 study to further investigate the drug's efficacy and safety.
The news is highly relevant to Biogen as it directly pertains to one of their investigational therapies, BIIB080. The promising results from the Phase 1b study could potentially lead to a new treatment for Alzheimer's disease, which would significantly impact the company's product portfolio and future revenues. The initiation of the Phase 2 study further indicates progress in the drug's development. Therefore, this news is likely to have a positive impact on Biogen's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100